Cost-effectiveness of camrelizumab plus rivoceranib for advanced hepatocellular carcinoma in the context of regional disparities in China
The combination of camrelizumab and rivoceranib as a treatment strategy not only improves health outcomes but also represents a cost-effective option across different developmental regions in China.
Authors
- Shiping Wen (ORCID: https://orcid.org/0000-0002-5048-0319)
- Xiongying Jiang (ORCID: https://orcid.org/0000-0003-4488-9326)
- Zhonghua Zhao
- Yanzhang Hao (ORCID: https://orcid.org/0000-0002-2325-9280)
Institutions
- Binzhou Medical University (CN)
- Shandong University of Aeronautics (CN)
- Sun Yat-sen University (CN)
- Sun Yat-sen Memorial Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-12-06
- DOI
- https://doi.org/10.3389/fonc.2024.1491404
- Citations
- 4
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.29